Quant Healthcare Fund
Direct · GrowthAI Summary
Quant Healthcare Fund has delivered strong outperformance versus the NIFTY 50 across all periods, with a 3Y fund CAGR of 20.17% against the benchmark's 4.9% and alpha of 14.99%. Its 3Y SIP XIRR of 15.73% trails the category average of 16.31%, while the 1Y XIRR of 15.8% comfortably beats the category's 10.72%. Long-term lump-sum CAGRs remain positive even over 15 years (4.14%) when the benchmark was near zero.
The fund shows a low beta of 0.78-0.82 and notably lower downside capture (61-73%) than upside capture (91-94%), indicating strong loss protection relative to the benchmark. It has experienced only 2 drawdown events greater than 10%, though recovery from the maximum drawdown took 487 days. The improving Calmar ratio from 0.64 (1Y) to 0.85 (3Y) suggests strengthening risk-adjusted returns over longer horizons.
The portfolio is a concentrated 15-stock healthcare fund, with the top 10 holdings accounting for roughly 79% of NAV and pharmaceuticals & biotechnology dominating at 79.5% sector weight. Top positions like GlaxoSmithKline Pharma (9.69%), Divi's Laboratories (9.63%), and Zydus Lifesciences (9.39%) are closely clustered, showing no single-stock dominance but high sector concentration. Non-healthcare exposure is minimal, limited to small allocations in food products and personal products.
The fund's 1Y SIP XIRR of 15.8% significantly outpaces the category average of 10.72%, but its 3Y XIRR of 15.73% is slightly below the category's 16.31%, indicating mid-pack performance over longer SIP horizons. Calendar year returns show volatility typical of sector funds, ranging from -4.8% in 2025 to 30.7% in 2024. Consistent positive alpha across 1Y to 15Y windows demonstrates durable benchmark outperformance.
This fund suits investors with high risk tolerance seeking tactical exposure to the healthcare and pharmaceutical sector, ideally as a satellite holding of 5-10% of a diversified portfolio rather than a core allocation. A time horizon of at least 5-7 years is advisable given sector cyclicality and the 487-day drawdown recovery period. Investors should be comfortable with concentrated sector risk and potential multi-year underperformance phases.
- Consistent positive alpha versus NIFTY 50 across all measured periods, from 21.26% (1Y) to 2.25% (15Y)
- Favorable asymmetry with downside capture of 61-73% well below upside capture of 91-94%, cushioning losses in market declines
- Low beta of 0.78-0.82 with only 2 drawdown events exceeding 10%, indicating relatively contained volatility for a sector fund
- Extreme sector concentration with 79.5% in pharmaceuticals & biotechnology exposes investors to regulatory, pricing, and USFDA-related risks specific to the pharma industry
- 3Y SIP XIRR of 15.73% trails the category average of 16.31%, and long-term category comparisons (5Y-12Y) are not available for the fund, limiting peer benchmarking
Generated on 13-10-2026, 3:12 AM. Verify before investing.
Gives more importance to longer time periods (10Y, 20Y) than shorter ones (1Y, 3Y). This balances out recent outperformance and gives a more realistic picture of what long-term returns might look like.
The largest peak-to-trough decline in the fund's NAV. Shows the worst-case loss an investor would have experienced at any point in the fund's history.
If you invested ₹1,00,000 every month via SIP, here's how this fund has historically performed across different time horizons.
| Duration | Invested | Median Value | XIRR | Min XIRR | Max XIRR |
|---|---|---|---|---|---|
| 1 Year | ₹12.00 L | ₹12.43 L | 17.6% | -27.4% | 81.9% |
| 3 Years | ₹36.00 L | ₹44.81 L | 15.3% | 10.6% | 19.1% |
SIP returns vs benchmark & category
Annualised SIP return (XIRR) over each rolling horizon — like-for-like, not lump-sum.
| Duration | Fund SIP XIRR | NIFTY 50 | Category avg | Fund edge |
|---|---|---|---|---|
| 1 Year | 17.6% | 14.3% | 10.7% | +3.3% |
| 3 Years | 15.3% | 11.0% | 16.3% | +4.3% |
| Duration | Mean | Median | Min | Max | Sharpe | Sortino | % Positive | Cat. Mean | Cat. Median |
|---|---|---|---|---|---|---|---|---|---|
| 1 Year | 16.1% | 9.4% | -12.3% | 67.6% | 0.43 | 1.53 | 76% | — | — |
| 3 Years | 21.2% | 21.4% | 18.5% | 22.6% | 15.02 | — | 100% | — | — |
Calmar Ratio by Duration
Compared against NIFTY 50
| Duration | Alpha | Beta | Upside Capture | Downside Capture | Fund CAGR | Bench CAGR |
|---|---|---|---|---|---|---|
| 1 Year | +18.59 | 0.76 | 85.7% | 60.5% | 11.5% | -11.4% |
| 3 Years | +13.01 | 0.81 | 91.9% | 74.0% | 18.5% | 5.3% |
| 5 Years | +8.79 | 0.81 | 92.2% | 71.9% | 12.4% | 2.9% |
| 7 Years | +5.77 | 0.81 | 92.2% | 71.9% | 8.7% | 2.1% |
| 10 Years | +3.59 | 0.81 | 92.2% | 71.9% | 6.0% | 1.4% |
| 12 Years | +2.77 | 0.81 | 92.2% | 71.9% | 5.0% | 1.2% |
| 15 Years | +1.94 | 0.81 | 92.2% | 71.9% | 4.0% | 1.0% |
| # | Stock | % of NAV |
|---|---|---|
| 1 | Glaxosmithkline Pharmaceuticals Ltd | 9.69% |
| 2 | Divi's Laboratories Ltd. | 9.63% |
| 3 | Zydus Lifesciences Limited | 9.39% |
| 4 | Glenmark Pharmaceuticals Ltd. | 9.34% |
| 5 | Strides Pharma Science Ltd | 9.04% |
| 6 | Torrent Pharmaceuticals Ltd. | 8.62% |
| 7 | Pfizer Ltd | 7.37% |
| 8 | IPCA Laboratories Ltd | 5.98% |
| 9 | Aurobindo Pharma Limited | 5.09% |
| 10 | Zydus Wellness Ltd | 4.90% |